Telescope installs second self-driving lab at Pfizer

Executive Summary

• Telescope Innovations Corp. has completed the installation of its second Self-Driving Laboratory (SDL) at Pfizer, marking a key milestone in transitioning from collaborative R&D to potential full-scale deployment under a multiyear agreement.
• The SDL is an autonomous physical AI platform designed to accelerate chemical synthesis development by up to 100 times compared to traditional manual methods, aiming to reduce timelines and generate significant cost savings in drug development.
• Management highlights the strategic value of the partnership, noting the platform's ability to compress development cycles and generate novel insights through real-time, closed-loop robotic automation.

Key Details

• Transaction: Installation of the second Self-Driving Laboratory (SDL) at Pfizer.
• Timeline: Installation completed in January 2026.
• Strategic Context: Part of a multiyear agreement between Telescope Innovations and Pfizer; marks a transition from collaborative R&D to potential full-scale deployment.
• Technology Capabilities:
  • Integrates collaborative robotics, real-time inline analytics (Process Analytical Technology or PAT), and machine-learning-guided experimental design.
  • Operates in a continuous, autonomous closed-loop workflow without researcher intervention.
  • Enables 24/7 operation across multiple reaction vessels simultaneously.
  • Sets up chemical reactions, measures kinetics in real time, and determines the next optimal experiment.
• Performance Metrics: Accelerates the development of chemical synthesis methods by up to 100 times compared with traditional manual approaches.
• Value Proposition: Significantly reduces development timelines and generates cost savings; enables acceleration of new innovations into the market.
• Scalability: Core closed-loop architecture is transferable to any domain requiring rapid optimization of chemical or materials processes, including advanced manufacturing.

Notable Quotes

• Henry Dubina, CEO: "The installation of our second SDL at one of the world's largest pharmaceutical companies is a testament to the strength of our ongoing partnership with Pfizer. Beyond the potentially significant cost savings during drug development, the SDL aims to compress the development cycles, which could enable the acceleration of new innovations into the market."
• Dr. Jason Hein, Founder and CTO: "With this second SDL deployment, we are pleased to continue demonstrating physical AI at work, moving beyond digital models into the real world of chemistry, where the platform generates novel insights that could not be obtained through simulation alone. The core closed-loop architecture is directly transferable to any domain that requires rapid optimization of chemical or materials processes, from pharmaceutical innovation to advanced manufacturing and beyond."